

Transparency notification received from S.R.I.W. SA and Sofipôle SA

Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings

Gosselies, Belgium, 11 December 2018, 7am CET– BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 4 December 2018 indicating that the shareholdings held by S.R.I.W. SA (Société Régional d'Investissement de Wallonie) and its subsidiary Sofipôle SA (Société Wallonne pour le Financement des Infrastructures des Pôles de Compétitivité) have passively crossed the threshold of 10% as a result of the issuance of new shares on 14 November 2018 following the conversion of convertible bonds issued on the private placement on 7 March 2018.

The notification dated 4 December 2018 contains the following information:

- Reason for the notification: Passive crossing of a threshold
- Notification by: A parent undertaking or a controlling person
- Persons subject to the notification requirement: S.R.I.W. SA & Sofipôle SA
- Transaction date: 14 November 2018
- Threshold that is crossed: 10%
- Denominator: 8,246,056
- Notified details:

Voting rights	Previous notification	After the transaction	
Holders of voting rights	# of voting rights	# of voting rights	% of voting rights
S.R.I.W. SA	344,530	344,530	4.18%
Sofipôle SA	474,093	474,093	5.75%
Total voting rights held by S.R.I.W and Sofipôle	818,623	818,623	9.93%

- Full chain of controlled undertakings through which the holding is effectively held: The Walloon Region holds 98.78% of S.R.I.W. SA which controls 60% of the shares of Sofipôle SA.

The notification can be consulted on the website of Bone Therapeutics, under the heading [Regulated information](#).

● **About Bone Therapeutics**

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics' technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company's primary clinical focus is ALLOB, an allogeneic "off-the-shelf" cell therapy platform derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

● **For further information, please contact:**

Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer
 Jean-Luc Vandebroek, Chief Financial Officer

Tel: +32 (0) 71 12 10 00

investorrelations@bonetherapeutics.com

For Belgium Media Enquiries

Comfi

Laure-Eve Monfort, Sabine Leclercq

Tel: +32 (0)2 290 90 93, +32 (0)2 290 90 91

monfort@comfi.be, sabine.leclercq@comfi.be

For International Media Enquiries:

Consilium Strategic Communications

Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville

Tel: +44 (0) 20 3709 5701

bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:

**NewCap Investor Relations
& Financial Communications**

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

Tel: + 33 (0)1 44 71 94 94

bone@newcap.eu

For US Media and Investor Enquiries:

Westwicke Partners

John Woolford

Tel: + 1 443 213 0506

john.woolford@westwicke.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
